These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21898060)

  • 1. Repeat etanercept administration restores clinical response of patients with rheumatoid arthritis.
    Wakabayashi H; Sudo A; Nishioka Y; Hasegawa M; Minami Y; Nishioka K
    Rheumatol Int; 2012 Nov; 32(11):3675-8. PubMed ID: 21898060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Etanercept in rheumatoid arthritis patients with a poor therapeutic response to infliximab].
    Sanmartí R; Gómez-Puerta JA; Rodríguez-Cros JR; Albaladejo C; Muñoz-Gómez J; Cañete JD
    Med Clin (Barc); 2004 Mar; 122(9):321-4. PubMed ID: 15033049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
    J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
    Hyrich KL; Lunt M; Watson KD; Symmons DP; Silman AJ;
    Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
    J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
    González-Gay MA; Agudo M
    Med Clin (Barc); 2010 May; 134(15):684-5. PubMed ID: 20176386
    [No Abstract]   [Full Text] [Related]  

  • 8. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
    Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
    Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
    Buch MH; Bingham SJ; Bejarano V; Bryer D; White J; Reece R; Quinn M; Emery P
    Arthritis Rheum; 2007 Apr; 57(3):448-53. PubMed ID: 17394231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
    Morales-Lara MJ; Cañete JD; Torres-Moreno D; Hernández MV; Pedrero F; Celis R; García-Simón MS; Conesa-Zamora P
    Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients.
    Li S; Kaur PP; Chan V; Berney S
    Clin Rheumatol; 2009 Jul; 28(7):787-91. PubMed ID: 19291350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of switching anti-TNF drugs in rheumatoid arthritis--a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN).
    Virkki LM; Valleala H; Takakubo Y; Vuotila J; Relas H; Komulainen R; Koivuniemi R; Yli-Kerttula U; Mali M; Sihvonen S; Krogerus ML; Jukka E; Nyrhinen S; Konttinen YT; Nordström DC
    Clin Rheumatol; 2011 Nov; 30(11):1447-54. PubMed ID: 21644062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis.
    Canhão H; Rodrigues AM; Mourão AF; Martins F; Santos MJ; Canas-Silva J; Polido-Pereira J; Pereira Silva JA; Costa JA; Araújo D; Silva C; Santos H; Duarte C; da Silva JA; Pimentel-Santos FM; Branco JC; Karlson EW; Fonseca JE; Solomon DH
    Rheumatology (Oxford); 2012 Nov; 51(11):2020-6. PubMed ID: 22843791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.
    Wick MC; Ernestam S; Lindblad S; Bratt J; Klareskog L; van Vollenhoven RF
    Scand J Rheumatol; 2005; 34(5):353-8. PubMed ID: 16234182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.
    Iannone F; Trotta F; Montecucco C; Giacomelli R; Galeazzi M; Matucci-Cerinic M; Ferri C; Cutolo M; Maria Bambara L; Triolo G; Ferraccioli G; Valentini G; Lapadula G;
    Ann Rheum Dis; 2007 Feb; 66(2):249-52. PubMed ID: 16837489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tumour necrosis factor alpha antagonists in established rheumatoid arthritis: effectiveness comparative study].
    Arenere Mendoza M; Manero Ruiz FJ; Carrera Lasfuentes P; Navarro Aznárez H; Pecondón Español A; Rabanaque Hernández MJ
    Med Clin (Barc); 2010 May; 134(15):665-70. PubMed ID: 20363004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
    Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF
    Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study.
    Fleischmann R; Goldman JA; Leirisalo-Repo M; Zanetakis E; El-Kadi H; Kellner H; Bolce R; DeHoratius R; Wang J; Decktor D
    Curr Med Res Opin; 2014 Nov; 30(11):2139-49. PubMed ID: 25050591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
    Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
    J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.